台股 » 健亞 » 個股財報 » 每月營收

健亞

(4130)
可現股當沖
  • 股價
    20.80
  • 漲跌
    ▲0.10
  • 漲幅
    +0.48%
  • 成交量
    100
  • 產業
    上櫃 生技醫療類股 ▲0.47%
  • 本地時間:13:30

    151人加入追蹤

    立即追蹤

健亞 (4130) 財務報表-每月營收
月營收報表

因應IFRSs國際會計準則,本報表在2013年以前為「個別營收」,2013年以後為「合併營收」。

健亞 (4130) 月營收分析比較圖

健亞 (4130) 月營收報表

年度/月份營業收入(單位:千元)累計營業收入(單位:千元)
單月營收去年同月營收單月月增率單月年增率累計營收去年累計營收累積年增率
2024/1137,84641,188-9.2%-8.1%472,174494,573-4.5%
2024/1041,69344,320-2.7%-5.9%434,328453,385-4.2%
2024/0942,85544,7362.3%-4.2%392,635409,065-4%
2024/0841,90847,1360.7%-11.1%349,780364,329-4%
2024/0741,61345,187-1.3%-7.9%307,872317,193-2.9%
2024/0642,15847,122-5.6%-10.5%266,259272,006-2.1%
2024/0544,65650,63411.4%-11.8%224,101224,884-0.3%
2024/0440,08642,675-21.5%-6.1%179,445174,2503%
2024/0351,06452,22159.2%-2.2%139,359131,5755.9%
2024/0232,08135,846-42.9%-10.5%88,29579,35411.3%
2024/0156,21443,50865.6%29.2%56,21443,50829.2%
2023/1233,93928,303-17.6%19.9%528,512438,75920.5%
2023/1141,18843,194-7.1%-4.6%494,573410,45620.5%
2023/1044,32043,790-0.9%1.2%453,385367,26223.5%
2023/0944,73637,153-5.1%20.4%409,065323,47226.5%
2023/0847,13638,8464.3%21.3%364,329286,31927.2%
2023/0745,18739,350-4.1%14.8%317,193247,47328.2%
2023/0647,12238,287-6.9%23.1%272,006208,12330.7%
2023/0550,63435,93618.6%40.9%224,884169,83632.4%
2023/0442,67534,234-18.3%24.6%174,250133,90030.1%
2023/0352,22135,17545.7%48.5%131,57599,66632%
2023/0235,84626,589-17.6%34.8%79,35464,49123%
2023/0143,50837,90253.7%14.8%43,50837,90214.8%
2022/1228,30340,565-34.5%-30.2%438,759434,2541%
2022/1143,19437,730-1.4%14.5%410,456393,6894.3%
2022/1043,79033,94617.9%29%367,262355,9593.2%
2022/0937,15339,498-4.3%-5.9%323,472322,0130.4%
2022/0838,84641,129-1.3%-5.6%286,319282,5151.3%
2022/0739,35037,5532.8%4.8%247,473241,3862.5%
2022/0638,28732,3356.5%18.4%208,123203,8332.1%
2022/0535,93636,9205%-2.7%169,836171,498-1%
2022/0434,23431,028-2.7%10.3%133,900134,578-0.5%
2022/0335,17534,93432.3%0.7%99,666103,550-3.8%
2022/0226,58922,851-29.8%16.4%64,49168,616-6%
2022/0137,90245,765-6.6%-17.2%37,90245,765-17.2%
2021/1240,56524,5117.5%65.5%434,254472,723-8.1%
新藥研發 浩鼎子公司抗癌新藥申請一期臨床 健亞明年完成試驗Anue鉅亨-2022/09/12
健亞 相關文章